斯鲁利单抗治疗肺鳞癌致肿瘤超进展1例

打开文本图片集

【中图分类号】R979.1 【文献标识码】A

【Abstract】This paper reports a 45-year-old female patient with lung squamous cell carcinoma who received chemotherapy for multiple systemic metastases，and then 171mg of the immune checkpoint inhibitor serplulimab was added，ivd，d1 （21 das a cycle）.After 2 cycles of treatment，the patient developed dizziness and nausea，and tumor brain metastasis was considered. The lung CT showed that the irregular mass shadow in the anterior segment of the upper lobe of the right lung was enlarged compared with the previous one，and MRI of the liver showed patchy abnormal signal in the liver segment IV.PET-CT showed that the lung， liver，adrenal gland， left groin and multiple bones wereallprogressed compared with the previous progres. It was considered to be tumor hyperprogresson caused by serplulimab.Serplulimab was immediately discontinued and methylprednisolone was given for symptomatic treatment，butthe patient stilldieddue to overprogression.The Naranjo's Assessment Scale was used to evaluate the correlation between the tumor progresson and serplulimab in this case，and the result was'likely to be related'.This case suggested that，the prognosis of tumor hyperprogression caused by immune checkpoint inhibitors has a poor prognosis，the clinical use of immune checkpoint inhibitors should bealert to this situation，and payattention toearlydifferential diagnosis and timelytreatmenttoavoid serious consequences.

【Keywords】 Serplulimab; Hyperprogresson; Immune checkpoint inhibitors; Adverse drug reaction

斯鲁利单抗是我国自主研发的程序性死亡受体-1（programmed death-1，PD-1）抑制剂，于2022年3月25日在我国首次获批上市，目前主要用于治疗微卫星高度不稳定型实体瘤、非小细胞肺癌、小细胞肺癌和食管鳞状细胞癌。（剩余9021字）